nQ Medical, a Digital Biomarker Discovery Platform, Unveils Latest COBRE Clinical Trial Results in Cognitive Impairment Across the AD Spectrum at AAN 2021 Annual Meeting
Share Article
The Cleveland Clinic’s COBRE trial explored monitoring of passive typing tasks as an indicator of cognitive impairment across the Alzheimer’s Disease Spectrum using nQ Medical’s Digital Biomarker Discovery Platform for diseases of cognition and motor. Detailed study findings will be presented at the American Academy of Neurology (AAN) Industry Therapeutic Update on Digital Cognitive Phenotyping In Neurodegenerative Disease: Modern Metrics For Clinical Science And Practice. Data will be shared by Justin Miller, PhD, neuropsychologist, and Aaron Ritter, MD, neurologist, Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV.
Lilly presents trial data on Alzheimer s drug showing promise parkrapidsenterprise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from parkrapidsenterprise.com Daily Mail and Mail on Sunday newspapers.
nQ Medical, a Digital Biomarker Discovery Platform, Unveils Latest Alzheimer’s Disease Clinical Trial Results at AD/PD 2021 International Conference
Share Article
nQ Medical’s Alzheimer’s Disease clinical trial studied passive typing monitoring as an indicator of cognitive impairment in the AD spectrum. Findings will be presented at the AD/PD Industry Symposium on Digital Cognitive Phenotyping in Neurodegenerative Disease: Impact of Digital on Neurology Practice.
nQ Medical s results, Alzheimer’s Disease study at Cleveland Clinic Lou Ruvo Center for Brain Health
nQ’s novel technology uses machine learning to capture and analyze an individual’s typing performance on keyboard or smartphone. Data is captured continuously, non-invasively, in a natural everyday environment, making it a very promising screening tool for early detection of Alzheimer’s disease.
Share this article
Share this article
NEW YORK, March 8, 2021 /PRNewswire/ The Alzheimer s Drug Discovery Foundation (ADDF) announced today that four of its funded researchers will be making presentations at the 15
th International Conference on Alzheimer s and Parkinson s Diseases (AD/PD™ 2021), which will be held virtually from Barcelona, Spain March 9-14, 2021. The ADDF seeks out and maintains a diverse portfolio of novel drug and biomarker targets that reflect the many biological pathways implicated in Alzheimer s disease, said Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF. We are excited to hear the latest updates from these investigators on some of the novel approaches we have supported since the early phases of research.